A Phase IIb Placebo-controlled Efficacy and Safety Study of Mocravimod as an Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HSCT

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Phase 2

Priothera SAS